1242268-17-2 Usage
Description
6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is a complex chemical compound featuring a spiro ring system with two carboxylate groups, a tert-butyl group, and an ethyl group attached at different positions. This unique molecular structure may confer potential biological activity, making it a candidate for pharmaceutical research and drug development.
Uses
Used in Pharmaceutical Research:
6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is used as a research compound for exploring its potential biological activity and applications in drug development. Its unique structure may offer novel therapeutic opportunities.
Used in Drug Development:
In the pharmaceutical industry, 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is used as a starting material or intermediate in the synthesis of new drugs. Its complex structure could lead to the discovery of innovative medications with specific therapeutic effects.
Further research and testing are required to fully understand the properties and potential uses of 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate, as its current applications are based on its structural characteristics and the possibilities they present in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1242268-17-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,2,2,6 and 8 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1242268-17:
(9*1)+(8*2)+(7*4)+(6*2)+(5*2)+(4*6)+(3*8)+(2*1)+(1*7)=132
132 % 10 = 2
So 1242268-17-2 is a valid CAS Registry Number.
1242268-17-2Relevant articles and documents
COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES
-
Page/Page column 142; 143; 144, (2020/12/07)
In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
GLP-1 Receptor Agonists and Uses Thereof
-
Paragraph 0473; 0475, (2020/01/04)
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS
-
Page/Page column 117, (2015/01/16)
Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
